Who are Allergovit Birch pollen's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): AllerT, Cupressus arizonica, tree 12 SQ-Bet, wasp venom, PURETHAL Grasses, 20.000 AUM/ml, HDM 12 SQ-HDM.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/allergovit-birch-pollen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Allergovit Birch pollen — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Allergovit Birch pollen (Allergovit Birch pollen) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Allergen immunotherapy. Area: Immunology / Allergy.

marketed Allergen immunotherapy Immunology / Allergy Biologic Live · refreshed every 30 min

Target snapshot

Allergovit Birch pollen (Allergovit Birch pollen) — Royal Sussex County Hospital. Allergovit Birch pollen is an allergen immunotherapy that desensitizes the immune system to birch pollen allergens through gradual exposure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Allergovit Birch pollen TARGET	Allergovit Birch pollen	Royal Sussex County Hospital	marketed	Allergen immunotherapy
AllerT	AllerT	Anergis	marketed	Allergen immunotherapy (peptide-based)	Allergen-derived peptide epitopes
Cupressus arizonica	Cupressus arizonica	Laboratorios Leti, S.L.	marketed	Allergen immunotherapy
tree 12 SQ-Bet	tree 12 SQ-Bet	Clinique Spécialisée en Allergies de la Capitale	marketed	Allergen immunotherapy (sublingual tablet)	Tree pollen allergens (IgE cross-linking epitopes)
wasp venom	wasp venom	Allergopharma GmbH & Co. KG	marketed	Allergen immunotherapy
PURETHAL Grasses, 20.000 AUM/ml	PURETHAL Grasses, 20.000 AUM/ml	HAL Allergy	marketed	Allergen immunotherapy extract	Grass pollen allergens (IgE and T-cell epitopes)
HDM 12 SQ-HDM	HDM 12 SQ-HDM	Clinique Spécialisée en Allergies de la Capitale	marketed	Allergen immunotherapy (sublingual tablet)	House dust mite allergens (Der p 1, Der p 2, Der f 1, Der f 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Allergen immunotherapy class)

Allergopharma GmbH & Co. KG · 8 drugs in this class
HAL Allergy · 2 drugs in this class
Medical University of Silesia · 2 drugs in this class
ALK-Abelló A/S · 2 drugs in this class
Laboratorios Leti, S.L. · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class
Royal Sussex County Hospital · 1 drug in this class
The University of Texas Medical Branch, Galveston · 1 drug in this class
University of Genova · 1 drug in this class
Anergis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Allergovit Birch pollen — Competitive Intelligence Brief. https://druglandscape.com/ci/allergovit-birch-pollen. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing